MesenCult™-SF Attachment Substrate

Serum-free attachment substrate for human mesenchymal stem cells

More Views

MesenCult™-SF Attachment Substrate

Serum-free attachment substrate for human mesenchymal stem cells

5 mg
Catalog #05424
359 USD

Required Products

Overview

MesenCult™-SF Attachment Substrate is a serum-free substrate for the in vitro culture of human mesenchymal stem and progenitor cells (MSCs). The substrate supports both expansion of human MSCs in vitro as well as their enumeration using the colony forming unit–fibroblast (CFU-F) assay.
Cell Type:
Mesenchymal Stem and Progenitor Cells
Species:
Human
Brand:
MesenCult

Scientific Resources

Educational Materials

(3)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications

(1)
Frontiers in immunology 2019

Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus.

C. Cantarelli et al.

Abstract

Current guidelines encourage administering pneumococcal vaccine Prevnar-13 to patients with lupus, but whether such vaccinations affect disease severity is unclear. To address this issue, we treated 3-month-old MRL-lpr mice, that spontaneously develop a lupus-like syndrome, with Prevnar-13 or vehicle control. After 3 months, we quantified circulating anti-Pneumococcal polysaccharide capsule (PPS) antibodies and signs of disease severity, including albuminuria, renal histology and skin severity score. We also compared immunophenotypes and function of T and B cells from treated and untreated animals. Prevnar-13 elicited the formation of anti-pneumococcal IgM and IgG. Prevnar-13 treated animals showed reduced albuminuria, renal histological lesions, and milder dermatitis compared to vehicle-treated controls. Mitigated disease severity was associated with reduced and increased T follicular helper cells (TFH) and T follicular regulatory cells (TFR), respectively, in Prevnar-treated animals. T cells from Prevnar-13 vaccinated mice showed differential cytokine production after aCD3/aCD28 stimulation, with significantly decreased IL-17 and IL-4, and increased IL-10 production compared to non-vaccinated mice. In conclusion, pneumococcal vaccination elicits anti-pneumococcal antibody response and ameliorates disease severity in MRL-lpr mice, which associates with fewer TFH and increased TFR. Together, the data support use of Prevnar vaccination in individuals with SLE.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.